C07D277/32

Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst

An oxidative homocoupling method of synthesizing certain 2,2-bithiophenes from thiophenes using oxygen as the terminal oxidant is disclosed. In non-limiting examples, the method uses oxygen along with a catalytic system that includes palladium, an assistive ligand, and a non-palladium metal additive to catalyze one of the following reactions: ##STR00001## Associated catalytic systems and compositions are also disclosed.

Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst

An oxidative homocoupling method of synthesizing certain 2,2-bithiophenes from thiophenes using oxygen as the terminal oxidant is disclosed. In non-limiting examples, the method uses oxygen along with a catalytic system that includes palladium, an assistive ligand, and a non-palladium metal additive to catalyze one of the following reactions: ##STR00001## Associated catalytic systems and compositions are also disclosed.

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Vector Control Compositions, Methods And Products Utilizing Same

The present inventions concerns use of a specific methoxyacrylate compound to control mosquitoes, and vector control products comprising that methoxyacrylate compound, in particular the invention relates to a substrate, to a composition, for controlling mosquitoes, and to a specific methoxyacrylate compound, processes for the synthesis of mosquitocidal methoxyacrylate compounds and new intermediates.

S1P3 Antagonists

The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.

S1P3 Antagonists

The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.

LMP7 inhibitors

The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

LMP7 inhibitors

The present disclosure provides compounds that are Large Multifunctional Protease 7 (LMP7) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of LMP7. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Analgesic compounds

Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.

Analgesic compounds

Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.